ArticleFrontiers in cardiovascular medicine2026
Effects of dapagliflozin on main pulmonary artery diameter in patients undergoing mitral valve replacement: a retrospective observational study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the effect of preoperative use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin on the perioperative main pulmonary artery (MPA) diameter in patients undergoing mitral valve replacement (MVR). Methods: This retrospective study analyzed 196 patients who underwent MVR at the Affiliated Hospital of Qingdao University between April 2020 and April 2025. Based on preoperative dapagliflozin use, patients were divided into a Dapagliflozin group ( Results: The baseline characteristics were balanced between the two groups. Postoperatively, the percentage change in MPA diameter was significantly lower in the Dapagliflozin group (-4.09% ± 16.77%) compared to the Control group (-2.21% ± 10.92%), with a statistically significant difference ( Conclusion: In patients undergoing mitral valve replacement, perioperative application of dapagliflozin was independently associated with a more stable and smaller main pulmonary artery diameter. This structural benefit was dissociated from changes in estimated pulmonary artery systolic pressure, suggesting that dapagliflozin may exert positive effects on the pulmonary artery via non-pressure-dependent direct vascular protective mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.